DermaVir: a novel topical vaccine for HIV/AIDS.

Human immunodeficiency virus (HIV) vaccines have the potential to improve antiretroviral drug treatment by inducing cytotoxic killing of HIV-infected cells. Prophylactic vaccines utilize new antigens to initiate immunity; however, in HIV-infected individuals the load of viral antigen is not the limiting factor for the restoration of immune responses. Here we describe a novel immunization strategy with DermaVir that improves viral antigen presentation using dendritic cells (DC). DermaVir contains a distinctive plasmid DNA expressing all HIV proteins except integrase to induce immune responses with broad specificity. The DNA is formulated to a mannosilated particle to target antigen-presenting cells and to protect the DNA from intracellular degradation. After topical application, DermaVir-transduced cells migrate from the skin to the draining lymph node and interdigitate as DermaVir-expressing, antigen-presenting DC. We compared the immunogenicity of topical and ex vivo DC-based DermaVir vaccinations in naive rhesus macaques. Both vaccinations induced simian immunodeficiency virus-specific CD4 helper and CD8 memory T cells detected by an in vivo skin test and an in vitro intracellular cytokine-based assay. Topical DermaVir vaccination represents an improvement upon existing ex vivo DC-based immunization technologies and may provide a new therapeutic option for HIV-infected patients.

[1]  D. Venzon,et al.  Protection against Mucosal Simian Immunodeficiency Virus SIVmac251 Challenge by Using Replicating Adenovirus-SIV Multigene Vaccine Priming and Subunit Boosting , 2004, Journal of Virology.

[2]  D. Venzon,et al.  Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants. , 2003, Vaccine.

[3]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[4]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Lisziewicz,et al.  Therapeutic vaccination for future management of HIV/AIDS. , 2003, Vaccine.

[6]  T. Geijtenbeek,et al.  Mycobacteria Target DC-SIGN to Suppress Dendritic Cell Function , 2003, The Journal of experimental medicine.

[7]  O. Schwartz,et al.  DC-SIGN Is the Major Mycobacterium tuberculosis Receptor on Human Dendritic Cells , 2003, The Journal of experimental medicine.

[8]  D. Watkins,et al.  Differences Between T Cell Epitopes Recognized After Immunization and After Infection1 , 2002, The Journal of Immunology.

[9]  H. Robinson,et al.  A new generation of HIV vaccines. , 2002, Trends in molecular medicine.

[10]  J. Lisziewicz,et al.  Quantification of HIV-specific CD8 T cells by in vitro stimulation with inactivated viral particles , 2002, AIDS.

[11]  C. Beck-Sague,et al.  Predictors of cytomegalovirus disease among pediatric transplant recipients within one year of renal transplantation , 2002, Pediatric transplantation.

[12]  J. Lisziewicz,et al.  Structured treatment interruptions for the management of HIV infection. , 2001, JAMA.

[13]  J. Lieberman,et al.  Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. , 2001, Blood.

[14]  J. Lisziewicz,et al.  Induction of Potent Human Immunodeficiency Virus Type 1-Specific T-Cell-Restricted Immunity by Genetically Modified Dendritic Cells , 2001, Journal of Virology.

[15]  S. Akira,et al.  Toll-like receptors: critical proteins linking innate and acquired immunity , 2001, Nature Immunology.

[16]  R. Paredes,et al.  HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection , 2001, AIDS.

[17]  G. M. Ortiz,et al.  The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection , 2001, AIDS.

[18]  R. Zinkernagel,et al.  Rapid Peptide Turnover and Inefficient Presentation of Exogenous Antigen Critically Limit the Activation of Self-Reactive CTL by Dendritic Cells1 , 2001, The Journal of Immunology.

[19]  L. Lefrançois,et al.  Preferential Localization of Effector Memory Cells in Nonlymphoid Tissue , 2001, Science.

[20]  A. Khoruts,et al.  Visualizing the generation of memory CD4 T cells in the whole body , 2001, Nature.

[21]  R Hoh,et al.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.

[22]  N. Letvin,et al.  DNA Vaccination for HIV-1 and SIV , 2001, Intervirology.

[23]  K. Hertogs,et al.  Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure , 2000, AIDS.

[24]  D. Hougaard,et al.  Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons. , 2000, AIDS research and human retroviruses.

[25]  J. Lisziewicz,et al.  Control of SIV rebound through structured treatment interruptions during early infection. , 2000, Science.

[26]  G. M. Ortiz,et al.  Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection , 2000, AIDS.

[27]  F. Sallusto,et al.  Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. , 2000, Science.

[28]  C. Mackay,et al.  T-cell function and migration. Two sides of the same coin. , 2000, The New England journal of medicine.

[29]  E. Rosenberg,et al.  Immune control of HIV-1 after early treatment of acute infection , 2000, Nature.

[30]  J. Mulé,et al.  Gene-modified dendritic cells for use in tumor vaccines. , 2000, Human gene therapy.

[31]  B. M. Flynn,et al.  Containment of Simian Immunodeficiency Virus Infection: Cellular Immune Responses and Protection from Rechallenge following Transient Postinoculation Antiretroviral Treatment , 2000, Journal of Virology.

[32]  A. Thomson,et al.  Transduction of dendritic cell progenitors with a retroviral vector encoding viral interleukin-10 and enhanced green fluorescent protein allows purification of potentially tolerogenic antigen-presenting cells. , 1999, Transplantation.

[33]  R. Crystal,et al.  Granulocyte-macrophage colony-stimulating factor gene transfer to dendritic cells or epidermal cells augments their antigen-presenting function including induction of anti-tumor immunity. , 1999, The Journal of investigative dermatology.

[34]  J. Lisziewicz,et al.  Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters. , 1999, AIDS research and human retroviruses.

[35]  J. Prieto,et al.  Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas , 1999, Gene Therapy.

[36]  N. Sato,et al.  Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. , 1999, Journal of immunology.

[37]  C. Caux,et al.  Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines , 1999, Journal of leukocyte biology.

[38]  A. Gambotto,et al.  Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL‐10, TGF‐β, and CTLA4Ig) , 1999, Journal of leukocyte biology.

[39]  I. Keet,et al.  Lymphoproliferative response to HIV type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDS-free infection. , 1999, AIDS research and human retroviruses.

[40]  J. Lisziewicz,et al.  Control of HIV despite the discontinuation of antiretroviral therapy. , 1999, The New England journal of medicine.

[41]  C. Pitcher,et al.  HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression , 1999, Nature Medicine.

[42]  S. Rowland-Jones,et al.  HIV: The deadly passenger in dendritic cells , 1999, Current Biology.

[43]  D. Montefiori,et al.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.

[44]  B. Stockinger,et al.  DNA Vaccination:  Transfection and Activation of Dendritic Cells as Key Events for Immunity , 1999, The Journal of experimental medicine.

[45]  J. Lifson,et al.  Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. , 1998, AIDS research and human retroviruses.

[46]  T. Tüting,et al.  DNA immunization targeting the skin: molecular control of adaptive immunity. , 1998, The Journal of investigative dermatology.

[47]  D. Escande,et al.  Polyethylenimine but Not Cationic Lipids Promotes Transgene Delivery to the Nucleus in Mammalian Cells* , 1998, The Journal of Biological Chemistry.

[48]  M A Nowak,et al.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. , 1998, Science.

[49]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[50]  S. Osmanov,et al.  Serotyping of HIV type 1 infections: definition, relationship to viral genetic subtypes, and assay evaluation. UNAIDS Network for HIV-1 Isolation and Characterization. , 1998, AIDS research and human retroviruses.

[51]  E. Rosenberg,et al.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. , 1997, Science.

[52]  J. Sodroski,et al.  Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys , 1997, Journal of virology.

[53]  R. Steinman,et al.  Dendritic cells in the T‐cell areas of lymphoid organs , 1997, Immunological reviews.

[54]  Hans Hengartner,et al.  Antigen localisation regulates immune responses in a dose‐ and time‐dependent fashion: a geographical view of immune reactivity , 1997, Immunological reviews.

[55]  J. Sodroski,et al.  An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys , 1996, Journal of virology.

[56]  F. Gage,et al.  In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.

[57]  B. Walker,et al.  Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. , 1996, Journal of immunology.

[58]  D. Scherman,et al.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[59]  R. Steinman,et al.  Maturation and migration of cutaneous dendritic cells. , 1995, The Journal of investigative dermatology.

[60]  H. Schuitemaker,et al.  Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics , 1995, The Journal of experimental medicine.

[61]  D. Ho,et al.  Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. , 1995, The New England journal of medicine.

[62]  M. Clementi,et al.  Dynamics of molecular parameters of human immunodeficiency virus type 1 activity in vivo , 1994, Journal of virology.

[63]  H. Matsue,et al.  Reciprocal cytokine-mediated cellular interactions in mouse epidermis : promotion of γδ T-cell growth by IL-7 and TNFα and inhibition of keratinocyte growth by γIFN , 1993 .

[64]  C. Fox,et al.  In situ hybridization in HIV research , 1993, Microscopy research and technique.

[65]  K. Wolff,et al.  Human epidermal T cells predominantly belong to the lineage expressing alpha/beta T cell receptor , 1990, Journal of Experimental Medicine.

[66]  J. Banchereau,et al.  Dendritic Cells: A Link Between Innate and Adaptive Immunity , 2004, Journal of Clinical Immunology.

[67]  W. Lu,et al.  Therapeutic dendritic-cell vaccine for simian AIDS , 2003, Nature Medicine.

[68]  D. Schadendorf,et al.  Autologous dendritic cells for treatment of advanced cancer--an update. , 2001, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[69]  E. Coligan.  Current protocols in immunology , 1991 .

[70]  R. Steinman,et al.  The dendritic cell system and its role in immunogenicity. , 1991, Annual review of immunology.